

- in pregnancy, 124e-4  
 primary mediastinal, 705  
 treatment of, 705-706
- Diffuse nontoxic goiter, 2301
- Diffuse white matter disease (leukoaraiosis), 174f, 2568, 2602
- Diffusion capacity of the lung for carbon monoxide (DL<sub>CO</sub>), 306e-5f, 306e-6, 1710
- Diffusion tensor imaging (DTI), 440e-8, 440e-9f
- Diffunisal, 724
- DiGeorge (velocardiofacial) syndrome, 83e-6, 375e-1, 465e-2, 2113, 2483
- Digitalis  
 action of, 265e-6  
 adverse effects of, 44, 203, 273e-3t, 1471t, 1477, 2365  
 ECG effects of, 1457  
 for pulmonary edema, 1763  
 for radiation-induced cardiovascular disease, 621  
 for SA node dysfunction, 1469
- Digital necrosis, in systemic sclerosis, 2159, 2159f
- Digital rectal examination, 482-483, 482t, 540, 580
- Digit span tests, 168, 183
- Digoxin  
 adverse effects of, 81, 727t, 1480t  
 for arrhythmias, 1479t, 1480t  
 for atrial fibrillation, 1487-1488  
 distribution of, 34  
 dosage of, 1479t, 1480t  
 drug interactions of, 34t, 42, 42t  
 azithromycin, 246e-4t  
 azoles, 246e-3t  
 PPIs, 1921  
 pyronaridine, 246e-12  
 for heart failure, 1512  
 metabolism of, 34t, 86e-9  
 overdose/poisoning with, 309-310, 473e-9t, 2764t  
 pharmacology of, 1479t, 1480t  
 for supraventricular arrhythmias, 1609  
 therapeutic monitoring of, 2764t  
 toxicity of, 42, 307, 312
- DIHS. *See* Drug-induced hypersensitivity syndrome (DIHS)
- Dihydroartemisinin, 246e-2t, 246e-7
- Dihydroergotamine  
 for exertional headache, 2597  
 for medication-overuse headache, 109  
 for migraine, 2591, 2592t, 2593t  
 nasal spray, 2591, 2592t  
 parenteral, 2591, 2592, 2592t
- Dihydrofolate (DHF) reductase  
 in antibiotic resistance, 931t, 934  
 in DNA synthesis, 641, 642f
- Dihydrofolate (DHF) reductase inhibitors, 246e-4t, 246e-12
- Dihydropteridine reductase (DHPR) deficiency, 434e-2t
- Dihydropteroate synthetase, 931t, 932, 934
- Dihydropyrimidinase deficiency, 431e-5t
- Dihydropyrimidine dehydrogenase, 39t
- Dihydropyrimidine dehydrogenase deficiency, 431e-5t, 431e-6, 431e-6f
- Dihydrorhodamine oxidation test, 423
- Dihydrotestosterone (DHT), 332, 2358, 2359f, 2759t. *See also* Testosterone
- 1,25-Dihydroxyvitamin D. *See also* Vitamin D  
 action of, 313, 313f, 2464-2465  
 overproduction of, 313, 314, 609t, 610  
 synthesis of, 387
- Diisocyanate exposure, 1692
- Dilated cardiomyopathy, 1556  
 alcohol-related, 1562  
 chemotherapy-related, 1562-1563  
 chest imaging in, 47e-4  
 in chronic kidney disease, 1817  
 clinical features of, 1554t  
 diagnosis of, 1554t, 1559-1560, 1559f  
 echocardiography in, 1557f  
 familial, 1555t, 1564-1565, 1564f  
 genetic considerations in, 436t, 1498, 1554, 1555t  
 heart failure in, 1501. *See also* Heart failure (HF)  
 in hemochromatosis, 1564, 1564f  
 in HIV infection, 1560  
 idiopathic, 1565  
 metabolic causes of, 1558t, 1563-1564  
 myocarditis and. *See* Myocarditis  
 natural history of, 1439  
 pathology of, 1557f  
 pathophysiology of, 372e-24t, 1556-1557, 1559f  
 Takotsubo (stress-related), 97, 289e-3, 1565  
 toxic, 1558t, 1562-1563  
 ventricular tachycardia in, 1495
- DILIN (Drug-Induced Liver Injury Network), 2025
- Diloxanide furoate, 246e-3t, 246e-8
- DILS (diffuse infiltrative lymphocytosis syndrome), 1260-1261
- Diltiazem  
 for accessory pathway-mediated tachycardia, 1483  
 adverse effects of, 1589t, 2218t  
 for aortic dissection, 1641  
 for arrhythmias, 1479t, 1480t  
 for atrial fibrillation, 1487  
 for AV nodal reentrant tachycardia, 1479  
 dosage of, 1479t, 1480t  
 drug interactions of, 246e-6t, 1590  
 for hypertension, 1624t, 1625  
 for hypertension in chronic kidney disease, 1821  
 for ischemic heart disease, 1589, 1589t  
 for NSTEMI-ACS, 1596  
 overdose/poisoning with, 473e-9t  
 pharmacology of, 1479t, 1480t  
 for Raynaud's phenomenon, 1649  
 for sex headache prevention, 2597  
 for supraventricular arrhythmia, 1609
- Dilute Russell's viper venom test, 406, 740
- Dimenhydrinate, 151t, 260, 260t
- Dimercaprol, 472e-2-3t
- D-Dimer test, 403, 407  
 in DIC, 737  
 in HIV infection, 1249t  
 in VTE/PE, 1632
- 1,3-Dimethylamylamine (DMAA), 14e-3
- Dimethyl fumarate (DMF), 2669t, 2670, 2671
- Dimethyl sulfoxide, 60e-4
- Dimorphic fungi, 1329, 1353
- Dipeptidyl peptidase-4 (DPP-IV) inhibitors, 2414-2415, 2414t, 2416
- Diphenhydramine  
 adverse effects of, 2640t  
 for anaphylaxis, 2117  
 for carcinoid syndrome, 566  
 for insomnia, 191  
 overdose/poisoning with, 473e-8t, 473e-13t  
 as premedication for antivenom, 2737  
 as premedication for taxanes, 103e-15  
 for prevention of dystonic reactions, 103e-25  
 for pruritus, 345
- Diphenoxylate, 272
- Diphenylhydantoin, 407, 569
- Diphosphoglycerate mutase (DGM) deficiency, 654t
- [<sup>99m</sup>Tc]Diphosphonate scintigraphy, 2224. *See also* Radionuclide scans/scintigraphy
- Diphtheria, 977  
 approach to the patient, 978  
 clinical features of, 978-979, 978f, 1471t, 1561, 2633  
 complications of, 979  
 cutaneous, 977, 978, 978f, 979  
 diagnosis of, 979  
 differential diagnosis of, 978  
 epidemiology of, 977  
 etiology of, 977  
 global considerations in, 977, 979  
 incidence pre- and postvaccine, U.S., 785t, 977  
 pathogenesis of, 977-978  
 pathology of, 978  
 prevention of, 787f, 980  
 prognosis of, 980  
 prophylaxis for close contacts, 980  
 treatment of, 979-980
- Diphtheria antitoxin, 979
- Diphtheria-tetanus-pertussis vaccine (DTaP), 929, 929t, 980, 1024. *See also* Tetanus, diphtheria, acellular pertussis (Tdap) vaccine
- Diphtheria-tetanus vaccine. *See* Tetanus-diphtheria vaccine
- Diphtheria vaccine, for travelers, 794
- Diphyllbothrium latum* (fish tapeworm), 245e-2t, 645, 1434
- Diploid, 426, 427
- Diplopia, 208  
 in abducens nerve palsy, 209  
 in horizontal gaze disorders, 209-210  
 monocular vs. binocular, 208  
 in multiple ocular nerve palsies, 209  
 in myasthenia gravis, 208. *See also* Myasthenia gravis  
 in nystagmus. *See* Nystagmus  
 in oculomotor nerve palsy, 208  
 in opsoclonus, 211  
 in supranuclear disorders of gaze, 209  
 in trochlear nerve palsy, 209
- Dipsogenic polydipsia, 2276, 2279
- Dipteran bite, 2749-2750
- Dipylidium caninum*/dipylidiasis, 1435
- Dipyridamole, 748, 748f, 1889t, 2570
- DIRA (deficiency of the IL-1 receptor antagonist), 2215
- Direct alloreactivity, 373e-5
- Direct antiglobulin (direct Coombs) test, 138e-4, 138e-4f
- Directional atherectomy catheter, 296e-2
- Direct thrombin inhibitors, parenteral, 443e-1, 753, 753t. *See also* Argatroban; Bivalirudin; Lepirudin
- Dirofilaria* infections, 1423
- Disability  
 assessment of, 1693  
 frailty and, 78-79  
 osteoarthritis-related, 2226  
 prevalence, in older population, 93e-4-5, 93e-4f
- Disability-adjusted life years (DALY), 9, 10f, 11t
- DISC1 gene mutations. *See* DiGeorge (velocardiofacial) syndrome
- Discectomy with fusion, cervical, 123
- Discoid (chronic cutaneous) lupus erythematosus  
 alopecia in, 355, 355t  
 clinical features of, 375  
 diagnosis of, 375  
 oral manifestations of, 237  
 skin manifestations of, 25e-3f, 76e-13f, 375, 376f, 2127-2128, 2129t  
 telangiectasias in, 357  
 treatment of, 375
- Discriminant function (DF) value, 2059
- Discrimination, 16e-4
- Disease  
 classification of, 87e-3, 87e-4f  
 definition of, 145e-1  
 genotype-phenotype relationships in, 87e-3, 87e-4f  
 germ theory of, 761  
 networks, 87e-3-4, 87e-5f, 87e-6f, 87e-7f  
 probability, measures of, 21-22
- Disease Control Priorities in Developing Countries*, 9, 10
- Disease-modifying antirheumatic drugs (DMARDs), 2145-2147, 2146-2147t
- Disequilibrium, 164. *See also* Balance
- DISH (diffuse idiopathic skeletal hyperostosis), 2172
- Disk/agar diffusion method, 150e-9
- Diskography, 440e-10
- Disk-space infection. *See* Osteomyelitis, vertebral
- Dislocation, 2219, 2219t